Ant Group Offloads Stakes to Focus on AI Chips Amid Nvidia Shortage

Ant Group divests from Orbbec and Youon, channeling funds to Alibaba and Huawei for Artificial Intelligence chip alternatives.

Ant Group has offloaded its shares in companies Orbbec and Youon, releasing capital for reinvestment into emerging technologies, especially amidst ongoing hardware shortages. The Chinese conglomerate, which has significant backing from Alibaba, is redirecting the funds from these sales towards innovative technology ventures and early-stage opportunities, as part of its broader strategy to enhance its technological capabilities.

The divestment includes over 556 million yuan for 8.82 million shares from Orbbec and 219 million yuan from Youon Technology. These transactions were strategically favorable, yielding significant returns on Ant Group´s initial investments. Each company has prospered since the initial rounds of funding, making these equity sales a profitable venture for Ant Group.

Part of Ant Group´s strategy involves capitalizing on Artificial Intelligence hardware alternatives by sourcing AI chips from Alibaba and Huawei, amid global shortages caused by restrictions on Nvidia exports from the U.S. The group´s pivot towards securing local chip alternatives signals a strategic move to sustain its AI and tech endeavors, reflecting Ant Group´s adaptability in an evolving tech landscape.

62

Impact Score

Compression and voice models reshape Artificial Intelligence efficiency

Recent releases focused on infrastructure rather than headline model breakthroughs, with gains in compression and voice systems pointing to lower inference costs and broader deployment. Google and Mistral highlighted two distinct paths for real-time audio, while TurboQuant targeted one of the most expensive bottlenecks in long-context inference.

Judge blocks Pentagon move against Anthropic

A federal judge temporarily blocked the Pentagon from labeling Anthropic a supply chain risk after finding major gaps between public threats, legal authority, and the government’s courtroom arguments. The dispute has become a test of how far the government can go in punishing an Artificial Intelligence company over political and contractual conflict.

Anumana wins FDA clearance for pulmonary hypertension ECG Artificial Intelligence tool

Anumana has received FDA 510(k) clearance for an Artificial Intelligence-enabled pulmonary hypertension algorithm designed for use with standard 12-lead electrocardiograms. The company says the software can help clinicians spot early signs of disease within existing workflows and without moving patient data outside the health system environment.

Contact Us

Got questions? Use the form to contact us.

Contact Form

Clicking next sends a verification code to your email. After verifying, you can enter your message.